Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Indaptus Therapeutics ( (INDP) ) has shared an update.
On February 11, 2026, Indaptus Therapeutics, Inc. entered into warrant repricing agreements with certain holders of 913,638 outstanding warrants originally issued in 2024 and 2025, cutting the exercise prices from a range of $8.30 to $47.60 down to $1.75 per share, the minimum price permitted under Nasdaq rules. As a condition of this repricing, those warrant holders agreed to vote all of their common shares in favor of every proposal at the special stockholder meeting set for February 26, 2026, while the board simultaneously reduced to $1.75 the exercise price of an additional 762,787 warrants from the same financings, leaving all other warrant terms unchanged and effectively realigning incentives and potentially easing future capital raising.
These coordinated moves significantly lower the cost for investors to exercise nearly 1.7 million warrants while securing supportive votes for upcoming corporate proposals, which may strengthen the company’s ability to implement strategic or financial measures put before shareholders. The repricing could increase the likelihood of warrant exercises, providing potential future equity funding, but it also concentrates voting support among participating investors for key decisions at the February 26, 2026 special meeting.
The most recent analyst rating on (INDP) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
Spark’s Take on INDP Stock
According to Spark, TipRanks’ AI Analyst, INDP is a Neutral.
The score is held down primarily by weak financial performance (no revenue, sizable ongoing losses, and continued cash burn alongside a diminished equity/asset base). Technicals also remain bearish with the stock trading below all major moving averages and a negative MACD, despite oversold readings. Valuation provides limited support due to negative earnings and no dividend, while recent corporate events are mixed but secondary to the financial and trend risks.
To see Spark’s full report on INDP stock, click here.
More about Indaptus Therapeutics
Indaptus Therapeutics, Inc. is a biotechnology company focused on developing therapeutic products, with its capital structure including common stock and various series of warrants issued through multiple financing rounds in 2024 and 2025. The company is listed on Nasdaq, and its corporate actions, such as warrant repricing and stockholder voting agreements, are structured to comply with exchange rules and support ongoing financing and governance needs.
Average Trading Volume: 730,242
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.06M
See more insights into INDP stock on TipRanks’ Stock Analysis page.